Responses
Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
80 Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden (TMB) and clinical utility for predicting response to pembrolizumab
Compose a Response to This Article
Other responses
No responses have been published for this article.